Donald P Lawrence

Donald P Lawrence

UNVERIFIED PROFILE

Are you Donald P Lawrence?   Register this Author

Register author
Donald P Lawrence

Donald P Lawrence

Publications by authors named "Donald P Lawrence"

Are you Donald P Lawrence?   Register this Author

48Publications

8327Reads

39Profile Views

Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies.

Neurology 2019 Sep 12;93(11):e1093-e1103. Epub 2019 Aug 12.

From the Departments of Neurology (D.D., W.S.D., A.C.G.), Medicine (K.L.R., D.F.C., J.V.C., D.P.L., M.J.M., R.J.S.), and Pathology (N.F.C.), Massachusetts General Hospital; Department of Neurology (D.D., A.A.A.), Brigham and Women's Hospital, Boston, MA; and Department of Neurology (D.D.), Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000008091DOI Listing
September 2019

Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.

Semin Arthritis Rheum 2019 Jun 16;48(6):1127-1132. Epub 2018 Oct 16.

Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00490172183044
Publisher Site
http://dx.doi.org/10.1016/j.semarthrit.2018.10.012DOI Listing
June 2019

The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity.

J Neurooncol 2018 Jun 16;138(2):299-306. Epub 2018 Feb 16.

Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 30 Fruit Street, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-018-2795-7DOI Listing
June 2018

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

J Am Coll Cardiol 2018 04 19;71(16):1755-1764. Epub 2018 Mar 19.

Cardiac MR PET CT Program, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2018.02.037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196725PMC
April 2018

Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors.

Ophthalmic Plast Reconstr Surg 2017 Sep/Oct;33(5):e114-e116

*Ophthalmic Plastic Surgery Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School; †Cancer Center, Massachusetts General Hospital, Harvard Medical School; and ‡Department of Ophthalmology, David C. Cogan Laboratory of Ophthalmic Pathology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, U.S.A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IOP.0000000000000833DOI Listing
September 2017

A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.

J Immunother 2017 04;40(3):108-113

*Massachusetts General Hospital Cancer Center †Department of Radiology, Massachusetts General Hospital, Harvard Medical School ‡Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000159DOI Listing
April 2017

A Symmetric Eczematous Eruption Harboring Thousands of Melanocytic Lesions.

JAMA Dermatol 2016 09;152(9):1021-4

Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2016.1150DOI Listing
September 2016

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.

PLoS One 2015 13;10(10):e0140310. Epub 2015 Oct 13.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, United States of America; Dermatology and Cutaneous Biology Research Center, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140310PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604168PMC
June 2016

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.

Cancer 2015 Nov 11;121(22):4007-15. Epub 2015 Aug 11.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29622DOI Listing
November 2015

Clinical significance of microscopic melanoma metastases in the nonhottest sentinel lymph nodes.

JAMA Surg 2015 May;150(5):465-72

Pathology Service and Dermatopathology Unit, Massachusetts General Hospital, Harvard Medical School, Boston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamasurg.2014.3843DOI Listing
May 2015

Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era.

J Neurooncol 2015 May 12;123(1):75-84. Epub 2015 Apr 12.

Harvard Radiation Oncology Program, 75 Francis Street, ASB1, L2, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-015-1761-xDOI Listing
May 2015

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008).

Cancer Immunol Immunother 2015 Apr 13;64(4):437-46. Epub 2015 Jan 13.

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, MSK 60th Street Outpatient Center, Suite 302, New York, NY, 10065, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-015-1653-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6730642PMC
April 2015

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

J Clin Oncol 2014 Nov 6;32(33):3697-704. Epub 2014 Oct 6.

Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.3535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226803PMC
November 2014

Isolation and molecular characterization of circulating melanoma cells.

Cell Rep 2014 May 18;7(3):645-53. Epub 2014 Apr 18.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Howard Hughes Medical Institute, Bethesda, MD 20815, USA. Electronic address:

View Article

Download full-text PDF

Source
http://www.cell.com/cell-reports/pdf/S2211-1247(14)00217-4.p
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S221112471400217
Publisher Site
http://dx.doi.org/10.1016/j.celrep.2014.03.039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079008PMC
May 2014

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

J Clin Oncol 2014 Apr 3;32(10):1020-30. Epub 2014 Mar 3.

Suzanne L. Topalian, William H. Sharfman, Julie R. Brahmer, Evan J. Lipson, Janis M. Taube, and Drew M. Pardoll, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Mario Sznol and Harriet M. Kluger, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; David F. McDermott, Beth Israel Deaconess Medical Center; Donald P. Lawrence, Massachusetts General Hospital Cancer Center; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Richard D. Carvajal, Memorial Sloan-Kettering Cancer Center, New York, NY; Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; Philip D. Leming, The Christ Hospital Cancer Center, Cincinnati, OH; Igor Puzanov and Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; David C. Smith, University of Michigan, Ann Arbor, MI; and Jon M. Wigginton, Georgia D. Kollia, and Ashok Gupta, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.0105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811023PMC
April 2014

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

Cancer Discov 2014 Jan 21;4(1):61-8. Epub 2013 Nov 21.

1Department of Medical Oncology, Dana-Farber Cancer Institute; 2Department of Medicine, Brigham and Women's Hospital; 3Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston; 4Broad Institute of Harvard and MIT; and 5Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0631DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947296PMC
January 2014

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes.

Oncoimmunology 2013 Oct 15;2(10):e26615. Epub 2013 Oct 15.

Department of Surgical Oncology; University of Texas MD Anderson Cancer Center; Houston, TX USA ; Department of Genomic Medicine; University of Texas MD Anderson Cancer Center; Houston, TX USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/onci.26615
Publisher Site
http://dx.doi.org/10.4161/onci.26615DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827093PMC
October 2013

Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma.

N Engl J Med 2013 Jul;369(2):173-83

Department of Medicine, Massachusetts General Hospital, Boston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMcpc1302332DOI Listing
July 2013

Case records of the Massachusetts General Hospital. Case 30-2010. A 15-year-old boy with a recurrent skin lesion.

N Engl J Med 2010 Sep;363(14):1352-60

Department of Dermatology, Massachusetts General Hospital, and Harvard Medical School, Boston, USA.

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMcpc1003889
Publisher Site
http://dx.doi.org/10.1056/NEJMcpc1003889DOI Listing
September 2010

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Cancer Res 2010 Jul 15;70(13):5213-9. Epub 2010 Jun 15.

Division of Surgical Oncology, Medical Oncology, and Dermatology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-0118DOI Listing
July 2010

Your patient with melanoma: staging, prognosis, and treatment.

Oncology (Williston Park) 2009 Jul;23(8 Suppl):13-21

Melanoma Disease Program, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
July 2009

Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients.

J Natl Cancer Inst Monogr 2004 (32):40-50

Hematology-Oncology Division, Tufts-New England Medical Center, Boston, MA 02111, USA.

View Article

Download full-text PDF

Source
https://academic.oup.com/jncimono/article-lookup/doi/10.1093
Publisher Site
http://dx.doi.org/10.1093/jncimonographs/lgh027DOI Listing
January 2005

The management of fatigue in cancer patients.

Oncology (Williston Park) 2004 Oct;18(12):1527-35; discussion 1536-8

Hematology/Oncology Division, Tufts-New England Medical Center, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
October 2004